Physician profile
Michael Obert
NPI 1487887709
$1,154.58
in general payments reported to CMS, 2019-2025
17 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $144 · 2023: $175 · 2024: $275 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $285.13 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $147.83 | 2021-2024 | Lokelma, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.78 | 2021-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $111.52 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $93.45 | 2022-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $86.07 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $75.96 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Philips North America LLC | $36.07 | 2023 | |
| Radius Health, INC. | $35.23 | 2023-2024 | Tymlos |
| Alexion Pharmaceuticals, INC. | $34.93 | 2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $23.05 | 2025 | Rexulti |
| Amgen INC. | $20.67 | 2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $20.05 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $16.09 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.69 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.35 | 2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Obert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.